Utama › Kanser Hati (Karsinoma Hepatoselular) › Washington
Kajian klinikal Kanser Hati (Karsinoma Hepatoselular) di Washington
15 kajian untuk Kanser Hati (Karsinoma Hepatoselular) sedang mencari peserta di lokasi di Washington.
Bandar di Washington
Teks kajian rasmi (Bahasa Inggeris)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 45 hingga 75 · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07227012A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0083, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07291076GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Fred Hutchinson Cancer Center, University of Washington, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Seattle
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06921785A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Mengambil peserta
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Jun 2026 · NCT05486572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Virginia Mason Medical Center, Seattle
- Summit Cancer Centers - North Spokane, Spokane
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Apr 2026 · NCT05440708Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia
- Northwest Medical Specialties PLLC (NWMS), Tacoma
Mengambil pesertaFasa 1
Umur 18 hingga 65 · Semua jantina · Dikemas kini 16 Mac 2026 · NCT07176650Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Seattle Children's Hospital, Seattle
Mengambil pesertaFasa 1
Umur 1 hingga 26 · Semua jantina · Dikemas kini 17 Feb 2026 · NCT07148050A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.